Therapy in diabetic dyslipidemia.

IF 1.2 4区医学 Q4 PHARMACOLOGY & PHARMACY

Indian Journal of Pharmacology Pub Date : 2026-03-01 Epub Date: 2026-03-02 DOI:10.4103/ijp.ijp_569_24

Uma Maheswari

{"title":"Therapy in diabetic dyslipidemia.","authors":"Uma Maheswari","doi":"10.4103/ijp.ijp_569_24","DOIUrl":null,"url":null,"abstract":"Introduction: Diabetics have an increased cardiovascular risk. This risk gets exaggerated by lipid abnormalities additionally. Diabetics have an increased propensity to develop dyslipidemia. Diabetic dyslipidemia is a cluster of lipoprotein abnormalities characterized by increased triglyceride and low-density lipoprotein levels, decreased high-density lipoprotein levels.Materials and methods: From the pilot study, a potent dose of saroglitazar and gemfibrozil was selected for this study. In this study, the experimental rats were divided into five groups of six animals in each group.Results: Combination therapy shows a decrease in lipid profile, atherogenic index, histopathological studies of different organs, and insulin levels compared to individual drugs and shows better therapeutic efficacy.Conclusion: Hence, the combination of saroglitazar and gemfibrozil has shown a good safety profile and may represent a novel therapeutic agent that will fulfill the unmet needs in T2DM and diabetic dyslipidemia.","PeriodicalId":13490,"journal":{"name":"Indian Journal of Pharmacology","volume":"58 2","pages":"109-113"},"PeriodicalIF":1.2000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13004564/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/ijp.ijp_569_24","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/2 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Diabetics have an increased cardiovascular risk. This risk gets exaggerated by lipid abnormalities additionally. Diabetics have an increased propensity to develop dyslipidemia. Diabetic dyslipidemia is a cluster of lipoprotein abnormalities characterized by increased triglyceride and low-density lipoprotein levels, decreased high-density lipoprotein levels.

Materials and methods: From the pilot study, a potent dose of saroglitazar and gemfibrozil was selected for this study. In this study, the experimental rats were divided into five groups of six animals in each group.

Results: Combination therapy shows a decrease in lipid profile, atherogenic index, histopathological studies of different organs, and insulin levels compared to individual drugs and shows better therapeutic efficacy.

Conclusion: Hence, the combination of saroglitazar and gemfibrozil has shown a good safety profile and may represent a novel therapeutic agent that will fulfill the unmet needs in T2DM and diabetic dyslipidemia.

Abstract Image

查看原文本刊更多论文

糖尿病性血脂异常的治疗。

糖尿病患者患心血管疾病的风险增加。血脂异常会进一步加剧这种风险。糖尿病患者发生血脂异常的倾向增加。糖尿病性血脂异常是一组脂蛋白异常，其特征是甘油三酯和低密度脂蛋白水平升高，高密度脂蛋白水平降低。材料和方法：从初步研究中，选择了一种有效剂量的沙格列他和吉非齐进行本研究。本研究将实验大鼠分为5组，每组6只。结果：与单用药物相比，联合治疗在血脂、动脉粥样硬化指数、不同器官组织病理学指标、胰岛素水平等方面均有降低，治疗效果更好。结论：因此，saroglitazar和gemfibrozil联合使用具有良好的安全性，可能是一种新的治疗药物，将满足2型糖尿病和糖尿病性血脂异常的需求。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Indian Journal of Pharmacology 医学-药学

CiteScore

4.00

自引率

4.20%

发文量

审稿时长

4-8 weeks

期刊介绍： Indian Journal of Pharmacology accepts, in English, review articles, articles for educational forum, original research articles (full length and short communications), letter to editor, case reports and interesting fillers. Articles concerning all aspects of pharmacology will be considered. Articles of general interest (e.g. methods, therapeutics, medical education, interesting websites, new drug information and commentary on a recent topic) are also welcome.